IPP Bureau
Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening
By IPP Bureau - February 07, 2026
Hologic has been at the forefront of cervical cancer screening for decades
Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating
By IPP Bureau - February 07, 2026
Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls
By IPP Bureau - February 06, 2026
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
By IPP Bureau - February 06, 2026
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure
By IPP Bureau - February 05, 2026
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Zydus receives FDA’s tentative approval for Dapagliflozin Tablets
By IPP Bureau - February 05, 2026
Lupin launches Topiramate ER capsules in US
By IPP Bureau - February 05, 2026
Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals
Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility
By IPP Bureau - February 05, 2026
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Novo Nordisk weathers pricing pressure, bets big on oral Wegovy
By IPP Bureau - February 05, 2026
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth
By IPP Bureau - February 05, 2026
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook
By IPP Bureau - February 05, 2026
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer
By IPP Bureau - February 05, 2026
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
FDA reviews AstraZeneca’s Saphnelo for subcutaneous use in Lupus
By IPP Bureau - February 05, 2026
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
GPT Healthcare reports 12% revenue growth in 9M FY26, strengthens clinical capabilities
By IPP Bureau - February 04, 2026
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Sanofi’s Venglustat shows breakthrough results in rare neurological Gaucher disease
By IPP Bureau - February 04, 2026
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
